Dashboard
Manage Tickers

NVCR NovoCure Ltd

Nasdaq novocure.com


$ 12.79 $ -0.01 (-0.08 %)    

Friday, 31-Oct-2025 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 12.81
$ 12.79
$ 12.46 x 40
$ 13.50 x 50
$ 12.47 - $ 13.01
$ 10.87 - $ 34.13
1,844,620
na
1.43B
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-24-2025 06-30-2025 10-Q
3 04-24-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 10-30-2024 09-30-2024 10-Q
6 07-25-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-22-2024 12-31-2023 10-K
9 10-26-2023 09-30-2023 10-Q
10 07-27-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 10-27-2022 09-30-2022 10-Q
14 07-28-2022 06-30-2022 10-Q
15 04-28-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 10-28-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 04-29-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 07-30-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-27-2020 12-31-2019 10-K
25 10-31-2019 09-30-2019 10-Q
26 07-25-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 02-28-2019 12-31-2018 10-K
29 10-25-2018 09-30-2018 10-Q
30 07-26-2018 06-30-2018 10-Q
31 04-26-2018 03-31-2018 10-Q
32 02-22-2018 12-31-2017 10-K
33 10-26-2017 09-30-2017 10-Q
34 07-27-2017 06-30-2017 10-Q
35 04-27-2017 03-31-2017 10-Q
36 02-23-2017 12-31-2016 10-K
37 11-02-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-01-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-novocure-raises-price-target-to-42
HC Wainwright & Co. Maintains Buy on NovoC...
10/30/2025 16:35:55

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $3...

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

novocure-q3-eps-033-beats-042-estimate-sales-167204m-beat-159189m-estimate
NovoCure Q3 EPS $(0.33) Beats $(0.42) Esti...
10/30/2025 11:01:05

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.42) by 2...

jp-morgan-maintains-neutral-on-novocure-lowers-price-target-to-23
JP Morgan Maintains Neutral on NovoCure, L...
10/27/2025 14:36:30

JP Morgan analyst Jessica Fye maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $25 to $23.

novocure-to-present-ttfields-data-at-eano-prague-oct-1619-and-esmo-berlin-oct-1721-highlights-radiosensitization-in-glioblastoma-and-panova-3-post-hoc-in-pancreatic-cancer
Novocure To Present TTFields Data At EANO ...
10/15/2025 11:02:03

novocure-to-present-final-results-from-phase-3-metis-trial-of-tumor-treating-fields-therapy-for-brain-metastases-from-nsclc-at-2025-astro
Novocure To Present Final Results From Pha...
09/29/2025 20:32:06

METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in pat...

japans-ministry-of-health-labour-and-welfare-approves-novocures-optune-lua-for-concurrent-use-with-pd-1pd-l1-inhibitors-for-adult-patients-with-unresectable-advancedrecurrent-non-small-cell-lung-cancer-who-have-progressed-on-or-after-platinum-based-chemotherapy
Japan's Ministry Of Health, Labour And Wel...
09/15/2025 11:03:45

Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields (TTF...

novocure-terminates-lunar-4-trial-decision-not-related-to-safety-concerns
NovoCure Terminates LUNAR-4 Trial, Decisio...
08/28/2025 11:13:16

novocure-expands-access-to-tumor-treating-fields-therapy-in-spain-for-adult-patients-with-newly-diagnosed-glioblastoma
Novocure Expands Access To Tumor Treating ...
08/25/2025 11:09:59

novocure-submits-premarket-approval-application-to-the-fda-for-tumor-treating-fields-therapy-for-locally-advanced-pancreatic-cancer
Novocure Submits Premarket Approval Applic...
08/20/2025 11:01:58

top-3-health-care-stocks-that-may-explode-in-july
Top 3 Health Care Stocks That May Explode ...
07/28/2025 10:52:30

wells-fargo-downgrades-novocure-to-equal-weight-lowers-price-target-to-145
Wells Fargo Downgrades NovoCure to Equal-W...
07/25/2025 13:22:13

Wells Fargo analyst Larry Biegelsen downgrades NovoCure (NASDAQ:NVCR) from Overweight to Equal-Weight and lowers the price t...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/24/2025 17:06:06

novocure-q2-2025-eps-036-beats-039-estimate-sales-158805m-beat-153876m-estimate
NovoCure Q2 2025 EPS $(0.36) Beats $(0.39)...
07/24/2025 11:00:57

Core News & Articles
Earnings Scheduled For July 24, 2025
07/24/2025 08:32:31

novocure-earnings-preview
NovoCure Earnings Preview
07/23/2025 21:02:00

this-circle-internet-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-tuesday
This Circle Internet Analyst Begins Covera...
07/08/2025 12:53:27

ladenburg-thalmann-initiates-coverage-on-novocure-with-buy-rating-announces-price-target-of-30
Ladenburg Thalmann Initiates Coverage On N...
07/08/2025 12:17:18

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on NovoCure (NASDAQ:NVCR) with a Buy rating and announces Price...

novocure-to-present-final-panova-3-secondary-data-at-esmo-gi-2025-ttfields-shows-pain-relief-qol-gains-in-pancreatic-cancer
Novocure To Present Final PANOVA-3 Seconda...
07/01/2025 11:09:41

demystifying-novocure-insights-from-4-analyst-reviews
Demystifying NovoCure: Insights From 4 Ana...
06/27/2025 18:01:19

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION